Arrhythmias & electrophysiology
High predicted durability for the novel small-diameter OmniaSecure defibrillation lead
Authors' conclusion
Consistent with early clinical trial experience, modeling projects highly durable 10-year performance of the OmniaSecure lead, including within the active adolescent pediatric population, which may uniquely benefit from a novel 4.7F defibrillation lead designed for reliability.
Study context
- Population
- Patients with ICDs (LEADR trial subset imaged in vivo)
- Outcome
- Projected fracture-free survival
- Follow-up
- 10 years
Methodological detailsvalidated reliability model, patient and bench test data, biplane fluoroscopy in LEADR trial subset
- Validated reliability model
- Patient and bench test data
- Biplane fluoroscopy in LEADR trial subset
Main finding
As reported in the abstract
OmniaSecure
98.2%
Further findings
| Outcome | Values |
|---|---|
| Projected fracture-free survival in adolescents · 10 years | OmniaSecure 97.9% |
Original publication
High predicted durability for the novel small-diameter OmniaSecure defibrillation lead. Heart Rhythm. Published 26 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →